Mironid

About:

Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.

Website: http://www.mironid.com/

Twitter/X: mironidltd

Top Investors: University of Strathclyde, European Investment Fund, Scottish Enterprise, Sofinnova Partners, BioGeneration Ventures

Description:

Mironid is a biotechnology company that focuses on drug discovery and development. Mironid builds and advances a pipeline of drug development programs targeting cAMP-degrading phosphodiesterase enzymes. The goal is to create novel and differentiated therapies for various diseases with significant unmet medical needs. The company specializes in identifying and validating novel drug targets, particularly in therapeutic areas such as cancer and neurodegenerative diseases. Mironid's work often involves using advanced technologies and methodologies to enhance the drug discovery process, aiming to bring innovative treatments to market more efficiently.

Total Funding Amount:

35M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Newhouse, North Lanarkshire, United Kingdom

Founded Date:

2014-01-01

Contact Email:

enquiries(AT)mironid.com

Founders:

Miles Houslay, Nigel Pyne, Paul Rodgers

Number of Employees:

11-50

Last Funding Date:

2023-09-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai